Théa and Unither Pharmaceuticals have agreed a long-term industrial partnership centred on a €140 million sterile ophthalmic manufacturing facility at Unither’s Gannat site in France.
The 20,000 sq m production unit will be primarily dedicated to Théa’s preservative-free eye treatments, including multidose bottles and single-dose formats. Planned annual capacity will exceed 50 million treatments once the operation reaches its intended scale.
Construction is scheduled for completion by the end of 2026, with pharmaceutical validation batches expected during 2027. Industrial operations are planned to begin in 2028, followed by the first commercial product launches in 2029.
The partners expect the investment to create 133 direct positions by 2028 and close to 250 by 2030. Théa will gain a larger European production base, while Unither will expand its contract development and manufacturing capacity for sterile, preservative-free dosage forms.
Ophthalmic manufacturing combines high-volume packaging with stringent microbiological and particulate control. A small container and apparently simple liquid product still require tightly controlled formulation, sterile processing, filling, closure, inspection, packaging, and batch release.
Products administered directly to the eye must remain sterile throughout their shelf life and deliver a controlled dose without introducing particles, contaminants, extractables, or leachables. Multidose products without preservatives create an additional engineering challenge because the container and dispensing mechanism must protect the formulation during repeated use.
The medicine and its packaging must therefore be developed as an integrated system. Container materials, valve geometry, drop formation, closure integrity, filling accuracy, and compatibility with the formulation all contribute to clinical and manufacturing performance.
Single-dose production creates a different set of constraints. High output must be balanced with reliable forming, filling, sealing, inspection, cutting, and counting, while each unit remains within specification across production runs extending into millions of doses.
Small deviations multiplied across that volume can generate substantial waste or batch investigation work. Process control, machine condition, environmental monitoring, and in-line inspection must identify drift before it affects a significant proportion of output.
The gap between construction completion and commercial launch reflects the validation burden attached to a new pharmaceutical plant. Utilities, cleanrooms, filling lines, sterilisation systems, environmental monitoring, laboratories, data systems, and cleaning processes must be commissioned and qualified before process performance can be demonstrated.
Regulators and customers will expect evidence that the plant can repeatedly manufacture each product within approved limits. Equipment installation is therefore followed by method transfer, operator training, media fills, cleaning validation, container closure testing, stability work, documentation, and regulatory submissions.
Specialist process capability is also being expanded in the UK, where Codis is targeting pharmaceutical spray drying capacity in Nottingham. The dosage forms differ markedly, although both projects seek to keep technically demanding development and manufacturing stages within an integrated industrial platform.
Regulated packaging capacity is developing alongside drug production. SÜDPACK’s expansion of cleanroom manufacturing for pharmaceutical packaging and sterile barrier systems demonstrates how product reliability depends on qualified materials and controlled production beyond the formulation process itself.
Dedicated capacity can give Théa greater control over supply, technical change, and product growth than reliance on available production slots in the wider contract manufacturing market. Demand for ophthalmic treatments is supported by ageing populations, chronic eye conditions, surgical activity, and the development of more specialised therapies.
Unither gains a long-term customer commitment capable of supporting the economics of a major sterile investment. Contract manufacturers require sufficient visibility before committing to cleanrooms, filling systems, laboratories, and skilled teams whose costs begin well before the first commercial batch is released.
Concentration remains an operational risk even within a dedicated partnership. Disruption to utilities, sterilisation, filling, packaging materials, or quality release could affect substantial product volumes, increasing the importance of spare parts, preventive maintenance, alternative capacity, and inventory planning.
Recruiting almost 250 employees will add another constraint. Sterile production requires microbiologists, validation engineers, maintenance technicians, automation specialists, quality personnel, laboratory analysts, operators, and supply staff who understand regulated manufacturing.
Training must begin long before routine operation because practical competence cannot be developed solely through written procedures. Gowning discipline, aseptic behaviour, intervention control, documentation, and deviation handling all require supervised experience.
The staged programme through 2029 recognises that physical construction is only one part of pharmaceutical industrialisation. A cleanroom can be complete while the processes inside it remain months or years from commercial approval.
Once validated, the Gannat facility will provide a substantial European platform for preservative-free ophthalmic products. Its performance will depend on maintaining sterility, packaging integrity, and batch consistency across more than 50 million treatments a year, an output level that leaves little tolerance for weak process discipline.
